Buspirone Safety in Elderly Patients with Dementia
Buspirone can be considered a relatively safe option for elderly patients with dementia, particularly for managing behavioral disturbances, as it is not listed among potentially inappropriate medications in the 2019 AGS Beers Criteria and FDA labeling shows similar safety profiles in elderly versus younger populations.
Evidence from Guidelines and FDA Labeling
The 2019 American Geriatrics Society Beers Criteria does not include buspirone among potentially inappropriate medications for older adults, including those with dementia 1. This is notable given that the Beers Criteria specifically warns against antipsychotics due to increased mortality risk in older adults with dementia 1.
FDA labeling data demonstrates reassuring safety in the elderly population:
- In a study of 6,632 patients receiving buspirone for anxiety, 605 patients were ≥65 years old and 41 were ≥75 years old 2
- Safety and efficacy profiles for elderly patients (mean age 70.8 years) were similar to younger populations (mean age 43.3 years) 2
- No age-related differences in pharmacokinetics were observed 2
- Post-marketing surveillance has not identified significant differences between elderly and younger patients, though greater sensitivity in some older patients cannot be ruled out 2
Clinical Efficacy Evidence in Dementia
Buspirone shows modest efficacy for behavioral disturbances in dementia:
- A retrospective study of 179 patients (mean age 83.8 years) with dementia showed 68.6% responded to buspirone, with 41.8% moderately to markedly improved for verbal and physical aggression 3
- Mean effective dose was 25.7 mg ± 12.5 mg daily 3
- A double-blind trial comparing buspirone 15 mg/day versus haloperidol 1.5 mg/day showed greater reduction in tension and anxiety with buspirone 4
- Case series demonstrate effectiveness for stereotypic movements and repetitive behaviors in dementia 5
Important Safety Considerations
Hepatic and renal impairment require caution:
- Buspirone is metabolized by the liver and excreted by the kidneys 2
- Patients with severe hepatic or renal impairment show increased plasma levels and prolonged half-life 2
- Administration cannot be recommended in severe hepatic or renal impairment 2
Rare but documented adverse effects:
- One case report documented oral dyskinesia in an elderly woman with advanced dementia after 3 days of buspirone, which persisted 4 months after onset 6
- This represents an isolated case but warrants monitoring for movement disorders
Drug interactions to monitor:
- Potential for prolonged prothrombin time when combined with warfarin 2
- May interfere with urinary metanephrine/catecholamine assays, requiring discontinuation 48 hours before testing 2
Clinical Approach
When considering buspirone for behavioral symptoms in elderly dementia patients:
- Start with standard dosing (typically 15-30 mg/day in divided doses), as elderly patients showed similar pharmacokinetics to younger adults 2
- Target symptoms most likely to respond: agitation, aggression, anxiety, and repetitive behaviors 3, 7, 5
- Monitor for movement disorders, though risk appears low 6
- Assess hepatic and renal function before initiation; avoid in severe impairment 2
- Consider buspirone as an alternative to antipsychotics, which carry increased mortality risk in dementia 1
Common pitfall: The 2014 expert panel on neuropsychiatric symptoms notes that psychotropics are unlikely to impact certain dementia behaviors including memory problems, repetitive verbalizations, wandering, and poor self-care 8. Buspirone should be reserved for anxiety, agitation, and aggression rather than these refractory symptoms.